Generic Drug Competition
The Senate Judiciary Committee has approved S. 369, the Preserve Access to Affordable Generics Act, which generally would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. As approved by the Committee, the bill would allow certain settlement agreements between drug companies if they enhance competition, and it would establish penalties for violations of the act.
